We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Exhibits New Hematology Analyzer in Middle East

By LabMedica International staff writers
Posted on 31 Jan 2019
Print article
Image: The DxH 900 hematology analyzer (Photo courtesy of Beckman Coulter).
Image: The DxH 900 hematology analyzer (Photo courtesy of Beckman Coulter).
Beckman Coulter (Brea, CA, USA) exhibited its DxH 900 hematology analyzer at MedLab Middle East, an international platform for laboratory management and medicine that brought together more than 700 exhibitors and over 35,000 professionals. MedLab Middle East 2019 took place at the Dubai International Convention and Exhibition Centre, Dubai, UAE, from February 4-7, 2019.

At the event, Beckman Coulter displayed its DxH 900 hematology analyzer, which allows mid- to high-volume clinical laboratories to perform complete blood count and white blood cell differential tests with minimal repeats. The DxH 900 analyzer offers advanced technologies to support patient care, by delivering the right results the first time. Foundational to the system are its core technologies, including the enhanced Coulter Principle, VCS 360 and DataFusion. These features offer high-resolution analysis of cells in their near-native states, providing a precise cellular assessment for excellent red blood cell, platelet and white blood cell test results on the first pass.

The DxH 900 analyzer demonstrates industry-leading 93% first-pass throughput, providing accurate flagging and reducing the number of slide reviews. This helps to generate reportable results as quickly as possible, reducing the time, supplies and costs that may be required for systems with higher repeat rates. Adding to this is the analyzer's lean reagent portfolio, which includes four reagents compared to 11 reagents required by other analyzers. Further, the DxH 900 features one of the smallest footprints in its class, making it highly efficient in utilization of laboratory space.

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Pathology

view channel
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.